Stellar Biotechnologies Q1 rev. up 34%, product sales rise 22% YoY.

• Stellar Biotechnologies reports Q1 2015 financial results • Product sales increase for core KLH business • Strong financial position maintained • Cash, cash equivalents, and short-term investments total $10.6 million • Net loss of $3.1 million • Revenue of $1.4 million • Operating expenses decrease to $4.5 million